Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00433576 · ClinicalTrials.gov registry record · Phase 1
Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery
A Phase 1 study of Adenocarcinoma of the Rectum and Adenocarcinoma of the Colon, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00433576 is a Phase 1 study of Adenocarcinoma of the Rectum and Adenocarcinoma of the Colon that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 20 participants, below the 910-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00433576, a Phase 1 study of Adenocarcinoma of the Rectum and Adenocarcinoma of the Colon, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial is studying the side effects and best dose of resveratrol in treating patients with colorectal cancer that can be removed by surgery. Resveratrol may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG resveratrol
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00433576
The ClinicalTrials.gov registry entry for NCT00433576 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (98% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Adenocarcinoma of the Rectum appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00433576 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT00433576 about?
NCT00433576 is a clinical study titled "Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery". This phase I trial is studying the side effects and best dose of resveratrol in treating patients with colorectal cancer that can be removed by surgery. Resveratrol may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00433576?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2006-12. Estimated completion is 2009-03.
What conditions does trial NCT00433576 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Rectum, Adenocarcinoma of the Colon, Stage III Colon Cancer, Stage III Rectal Cancer, Stage II Rectal Cancer.
What interventions are being tested in trial NCT00433576?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), resveratrol (DRUG).
Who is sponsoring clinical trial NCT00433576?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00433576 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Rectum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
COMPLETED · Phase 1
-
Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum
COMPLETED · Phase 1
-
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
COMPLETED · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
-
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.